<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Moyamoya disease and moyamoya syndrome: Etiology, clinical features, and diagnosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Moyamoya disease and moyamoya syndrome: Etiology, clinical features, and diagnosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Moyamoya disease and moyamoya syndrome: Etiology, clinical features, and diagnosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Nijasri Charnnarong Suwanwela, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">José Biller, MD, FACP, FAAN, FAHA</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Douglas R Nordli, Jr, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Glenn A Tung, MD, FACR</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard P Goddeau, Jr, DO, FAHA</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 11, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Moyamoya is an uncommon cerebrovascular condition characterized by progressive narrowing of large intracranial arteries and the secondary development of prominent small-vessel collaterals. These collateral vessels produce a characteristic smoky appearance on angiography, which was first called "moyamoya," a Japanese word meaning puffy, obscure, or hazy like a puff of smoke in the air.</p><p>Moyamoya is a progressive disorder that may lead to ischemic stroke or intracranial hemorrhage in children and adults.</p><p>This topic will review the etiologies, clinical features, and diagnosis of moyamoya. The prognosis and treatment of moyamoya are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1112.html" rel="external">"Moyamoya disease and moyamoya syndrome: Treatment and prognosis"</a>.)</p><p class="headingAnchor" id="H2195265364"><span class="h1">CLASSIFICATION AND TERMINOLOGY</span></p><p class="bulletIndent1"><span class="glyph">●</span>The term "moyamoya" describes the specific angiographic findings of unilateral or bilateral stenosis or occlusion of the arteries around the circle of Willis with prominent arterial collateral circulation  (<a class="graphic graphic_diagnosticimage graphicRef129102" href="/z/d/graphic/129102.html" rel="external">image 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Moyamoya disease (MMD) refers to patients with moyamoya angiographic findings who may have genetic susceptibilities but no associated conditions. This may also be called primary or idiopathic moyamoya disease as well as the descriptive "spontaneous occlusion of the circle of Willis" [<a href="#rid1">1,2</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Moyamoya syndrome (MMS) refers to patients with moyamoya angiographic findings who also have an associated medical condition as described below. (See <a class="local">'Associated conditions'</a> below.)</p><p></p><p class="bulletIndent1">These secondary forms of the condition have been termed "moyamoya phenomenon," "angiographic moyamoya," or "quasi-moyamoya disease" [<a href="#rid1">1,3-5</a>].</p><p></p><p class="headingAnchor" id="H1600366991"><span class="h1">ETIOLOGY AND PATHOGENESIS</span><span class="headingEndMark"> — </span>The etiology of MMD is unknown, but genetic associations have been identified. MMS has been associated with multiple conditions, which may implicate diverse pathophysiologic processes leading to the characteristic vascular abnormalities.</p><p class="headingAnchor" id="H915360997"><span class="h2">Genetic associations</span><span class="headingEndMark"> — </span>The high incidence among the Japanese population, together with a familial occurrence of approximately 10 to 15 percent of cases, strongly suggests a genetic etiology. Accumulating evidence suggests that the <em>RNF213</em> gene on chromosome 17q25.3 is an important susceptibility factor for MMD in populations in several East Asian countries [<a href="#rid6">6-14</a>].</p><p>Several reports have also linked familial MMD to chromosomes 3p24.2, p26, 6q25, 8q23, and 12p12 [<a href="#rid15">15-17</a>]. Although the mode of inheritance is not established, one study suggested that familial moyamoya is an autosomal dominant disease with incomplete penetrance [<a href="#rid18">18</a>]. The authors proposed that genomic imprinting and epigenetic modification may account for the predominantly maternal transmission and elevated female-to-male incidence ratio. (See <a class="local">'Epidemiology'</a> below and  <a class="medical medical_review" href="/z/d/html/2897.html" rel="external">"Inheritance patterns of monogenic disorders (Mendelian and non-Mendelian)", section on 'Parent-of-origin effects (imprinting)'</a>.)</p><p>A later genome-wide association study confirmed the relationship of MMD and a previously reported locus on chromosome 17q25 [<a href="#rid19">19</a>]. The study also identified 10 novel risk loci, including the genes regulating homocysteine metabolism, loci related to large vessel disease, and loci that are highly expressed in the immune system.</p><p class="headingAnchor" id="H3691773323"><span class="h2">Associated conditions</span><span class="headingEndMark"> — </span>There are many conditions associated with MMS. They may be causative or syndromic. Some of the conditions reported to be associated with MMS include:</p><p class="bulletIndent1"><span class="glyph">●</span>Disease affecting arteries around the circle of Willis</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Atherosclerosis [<a href="#rid20">20</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Radiation therapy to the base of the brain [<a href="#rid21">21</a>] (see  <a class="medical medical_review" href="/z/d/html/91670.html" rel="external">"Delayed complications of cranial irradiation", section on 'Cerebrovascular effects'</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Cranial trauma [<a href="#rid22">22</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Brain tumors [<a href="#rid23">23-25</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Meningitis [<a href="#rid26">26</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Other viral or bacterial infection (eg, <em>Cutibacterium</em> <em>acnes</em>, leptospirosis, human immunodeficiency virus [HIV]) [<a href="#rid27">27-29</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hematologic conditions</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Sickle cell disease [<a href="#rid30">30-32</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Beta thalassemia [<a href="#rid33">33</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Fanconi anemia [<a href="#rid34">34</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Hereditary spherocytosis [<a href="#rid35">35</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Homocystinuria and hyperhomocysteinemia [<a href="#rid36">36</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Factor XII deficiency [<a href="#rid37">37</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Essential thrombocythemia [<a href="#rid38">38</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Protein S deficiency [<a href="#rid39">39-41</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Pyruvate kinase deficiency [<a href="#rid42">42</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Vasculitis and autoimmune and multisystem diseases</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Systemic lupus erythematosus [<a href="#rid43">43</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Polyarteritis nodosa and postinfectious vasculopathy [<a href="#rid44">44</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Graves disease and thyroiditis [<a href="#rid45">45-48</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Sneddon syndrome and the antiphospholipid antibody syndrome [<a href="#rid49">49,50</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Anti-Ro and anti-La antibodies [<a href="#rid51">51</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Type 1 diabetes mellitus [<a href="#rid48">48</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Pulmonary sarcoidosis [<a href="#rid52">52,53</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Genetic and developmental disorders</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Alagille syndrome [<a href="#rid54">54,55</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Down syndrome [<a href="#rid56">56,57</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Hypomelanosis of Ito [<a href="#rid58">58</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Marfan syndrome [<a href="#rid59">59</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Microcephalic osteodysplastic primordial dwarfism type 2 [<a href="#rid60">60</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Multisystem disorder with short stature, hypergonadotropic hypogonadism, and dysmorphism [<a href="#rid61">61,62</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Neurofibromatosis type 1 [<a href="#rid63">63-66</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Noonan syndrome [<a href="#rid67">67-69</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Phakomatosis pigmentovascularis type IIIb [<a href="#rid70">70</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Prader-Willi syndrome [<a href="#rid71">71</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Pseudoxanthoma elasticum [<a href="#rid72">72</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Sturge-Weber syndrome [<a href="#rid73">73</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Tuberous sclerosis [<a href="#rid74">74</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Turner syndrome [<a href="#rid75">75</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Williams syndrome [<a href="#rid76">76</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Morning glory optic disc anomaly  (<a class="graphic graphic_diagnosticimage graphicRef55325" href="/z/d/graphic/55325.html" rel="external">image 2</a>), usually in conjunction with other craniofacial abnormalities [<a href="#rid77">77-79</a>] (see  <a class="medical medical_review" href="/z/d/html/6267.html" rel="external">"Congenital and acquired abnormalities of the optic nerve", section on 'Morning glory disc'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other vasculopathies and extracranial cardiovascular diseases</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Coarctation of the aorta [<a href="#rid80">80</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Congenital heart disease [<a href="#rid81">81</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Fibromuscular dysplasia [<a href="#rid82">82</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Renal artery stenosis [<a href="#rid83">83</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Metabolic diseases</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Type I glycogenosis [<a href="#rid84">84,85</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Hyperphosphatasia [<a href="#rid86">86</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Primary oxalosis [<a href="#rid87">87</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Renal disorders</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Polycystic kidney disease [<a href="#rid88">88-90</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Wilms tumor [<a href="#rid83">83,91-103</a>]</p><p></p><p class="headingAnchor" id="H2050095689"><span class="h2">Pathogenesis</span><span class="headingEndMark"> — </span>The pathophysiologic processes leading to arterial stenosis and small vessel collateralization involve vessel wall thickening and angiogenesis. A genetic susceptibility may be implicated in MMD, while underlying associated conditions trigger the development of MMS.</p><p>Vascular changes in moyamoya may be related to impaired response to inflammation or defects in cellular repair mechanisms [<a href="#rid104">104</a>]. Such changes have been associated with evidence of increased angiogenesis-related factors, including endothelial colony-forming cells, various cytokines, vascular endothelial growth factor (VEGF), and basic fibroblast growth factor (bFGF) [<a href="#rid105">105-107</a>]. High levels of fibroblast growth factor, which may stimulate arterial growth, have been found in the vascular intima, media, and smooth muscle as well as cerebrospinal fluid among patients with moyamoya [<a href="#rid108">108,109</a>]. Transforming growth factor beta-1 (TGFB1), which mediates neovascularization, may also contribute to the pathogenesis [<a href="#rid110">110,111</a>]. High levels of hepatocyte growth factor (a strong inducer of angiogenesis) have been detected in the carotid fork and cerebrospinal fluid in patients with moyamoya [<a href="#rid112">112</a>].</p><p class="headingAnchor" id="H2827532550"><span class="h2">Pathologic findings</span><span class="headingEndMark"> — </span>Tissue analysis in patients with moyamoya shows evidence of arterial vessel narrowing and secondary vascular proliferation characteristic of the disease as well as tissue damage related to the vascular abnormalities.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stroke</strong> – Brain tissue of patients with moyamoya usually reveals evidence of prior ischemic or hemorrhagic stroke. Multiple areas of cerebral infarction and focal cortical atrophy are commonly found. Although large-vessel stenosis and occlusion are the hallmark of this disease, extensive territorial infarction is uncommon. The brain infarcts are generally small and located in the basal ganglia, internal capsule, thalamus, and subcortical regions [<a href="#rid113">113</a>]. However, the cause of death in most autopsy cases is intracerebral hemorrhage [<a href="#rid93">93</a>]. The hemorrhage is commonly found in the basal ganglia, thalamus, hypothalamus, midbrain, and/or periventricular region. Bleeding into the intraventricular space is frequently observed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vascular stenosis</strong> – Pathologic vascular lesions appear in the large vessels of the circle of Willis and in the small collateral vessels [<a href="#rid94">94</a>]. The terminal portions of the internal carotid arteries as well as the proximal middle and anterior cerebral arteries are most commonly involved [<a href="#rid114">114</a>]. Some patients may have unilateral stenosis at presentation, although progression to bilateral involvement may occur [<a href="#rid115">115,116</a>]. Less frequently, the posterior circulation is affected, especially the posterior cerebral artery.</p><p></p><p class="bulletIndent1">In the affected large arteries, variable stenosis or occlusion is associated with intimal fibrocellular thickening, tortuosity or duplication of the internal elastic lamina, and attenuation of the media [<a href="#rid91">91,117-119</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Collateral vessels</strong> – One of the hallmarks of moyamoya is the presence of a collateral meshwork of overgrown and dilated small arteries, the moyamoya vessels, that branch from the circle of Willis  (<a class="graphic graphic_diagnosticimage graphicRef129103" href="/z/d/graphic/129103.html" rel="external">image 3</a>).</p><p></p><p class="bulletIndent1">The pathology of the smaller perforating vessels in moyamoya is variable. Morphometric analysis suggests that some are dilated with relatively thin walls, while others are stenotic with thick walls [<a href="#rid117">117</a>]. Dilated vessels, more common in younger patients than in adults, tend to show fibrosis with attenuation of the media and microaneurysm formation. Histologic study from autopsy specimens of aneurysms showed disappearance of internal elastic lamina and media [<a href="#rid92">92</a>]. These findings are similar to those of the berry aneurysms commonly observed in primary subarachnoid hemorrhage.</p><p></p><p class="bulletIndent1">Leptomeningeal vessels are another source of collaterals in moyamoya. As a result of intracranial internal carotid artery stenosis, leptomeningeal anastomoses may develop from the three main cerebral arteries (middle, anterior, and posterior). These collaterals result from dilatation of preexisting arteries and veins. In addition, transdural anastomoses, termed vault moyamoya, may develop from extracranial arteries such as the middle meningeal and superficial temporal arteries [<a href="#rid95">95</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Aneurysms</strong> – Cerebral aneurysms have been associated with moyamoya in a number of reports [<a href="#rid96">96-100</a>]. Aneurysms can develop at vessel branching points in the circle of Willis or along collateral vessels [<a href="#rid101">101,120</a>]. In a review of 111 moyamoya patients with cerebral aneurysm, most presented with intracranial hemorrhage and were found to have a single aneurysm in 86 percent of cases. Aneurysms along the circle of Willis were found in 56 percent, of which almost 60 percent were in the posterior circulation [<a href="#rid120">120</a>].</p><p></p><p class="bulletIndent1">Aneurysms can also arise from the small collateral moyamoya vessels, choroidal arteries, or other peripheral collateral arteries [<a href="#rid101">101</a>]. These small-vessel aneurysms are the major cause of parenchymal (intracerebral) hemorrhage in moyamoya.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Extracranial involvement</strong> – In patients with moyamoya, stenosis due to fibrocellular intimal thickening may also affect the extracranial and systemic arteries, including the cervical carotid, renal, pulmonary, and coronary vessels [<a href="#rid91">91,102</a>].</p><p></p><p class="bulletIndent1">Involvement of the renal arteries has been most frequently reported. In one study of 86 patients with MMD, six had renal artery stenosis, two had associated renovascular hypertension, and one had a renal artery aneurysm [<a href="#rid83">83</a>]. Similarly, in a later study of 73 consecutive patients with MMD, four had renal artery stenosis [<a href="#rid121">121</a>].</p><p></p><p class="headingAnchor" id="H539090095"><span class="h1">EPIDEMIOLOGY</span></p><p class="headingAnchor" id="H708387298"><span class="h2">Incidence and prevalence</span><span class="headingEndMark"> — </span>The relative prevalence of MMD and MMS vary geographically. MMD is more common in East Asian countries than elsewhere, with the highest prevalence found in Japan, China, and Korea [<a href="#rid114">114,122,123</a>].</p><p>In epidemiologic surveys conducted in Japan, the following observations have been made [<a href="#rid124">124-127</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The annual incidence of moyamoya is 0.35 to 0.94 per 100,000 population.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The prevalence of moyamoya is 3.2 to 10.5 per 100,000 population.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There is a female predominance, with a female-to-male ratio of 1.9.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A family history of MMD is present in 10 to 12 percent of patients.</p><p></p><p>Using hospital admissions data, a United States study found an incidence of 0.57 per 100,000 persons/year [<a href="#rid128">128</a>]. Among ethnic groups in California, the moyamoya incidence rate for Asian Americans was 0.28 per 100,000, similar to that in Japan. The incidence rates were lower for African American, White American, and Hispanic populations (0.13, 0.06, and 0.03 per 100,000, respectively). The incidence of MMS in Japan is approximately 10 times lower than MMD [<a href="#rid129">129,130</a>].</p><p class="headingAnchor" id="H2138137616"><span class="h2">Age distribution</span><span class="headingEndMark"> — </span>MMD and MMS both occur in children and adults; presentation in infancy is uncommon [<a href="#rid131">131,132</a>]. Data from a nationwide registry in Japan, with 2545 cases of MMD, showed a bimodal distribution in the age of onset, with one peak at approximately 10 years of age and a second broader peak at approximately 40 years of age [<a href="#rid127">127</a>]. A cohort study of 802 patients with MMD from China also demonstrated a bimodal age distribution, with a major peak at five to nine years of age and another peak at 35 to 39 years of age [<a href="#rid133">133</a>].</p><p class="headingAnchor" id="H6"><span class="h1">CLINICAL PRESENTATIONS</span><span class="headingEndMark"> — </span>Moyamoya has varying clinical presentations; the expression of disease and the age at presentation are influenced by regional and ethnic differences.</p><p class="headingAnchor" id="H3977709611"><span class="h2">Ischemic stroke and transient ischemic attack</span><span class="headingEndMark"> — </span>The most common initial presentation of moyamoya is ischemic stroke [<a href="#rid134">134-138</a>]. Transient ischemic attack (TIA) is also a frequent initial presentation and may be recurrent [<a href="#rid134">134,138</a>].</p><p>In one retrospective series from the United States, 61 percent of 31 adults with MMD or MMS presented with ischemic symptoms; in those with stroke, the predominant pattern was a border-zone pattern of infarction [<a href="#rid137">137</a>]. In another retrospective study, 21 German patients with MMD all presented with ischemic events, including 16 who were adults at symptom onset [<a href="#rid136">136</a>].</p><p>In children, symptomatic episodes of ischemia in the anterior and middle cerebral artery vascular territories<em> </em>may commonly be triggered by exercise, crying, coughing, straining, fever, or hyperventilation [<a href="#rid104">104,139,140</a>]. In the International Pediatric Stroke Study involving 174 children with moyamoya, ischemic stroke was the initial presentation in 90 percent of children and TIA in 7.5 percent [<a href="#rid134">134</a>]. Ischemic symptoms of hemiparesis or speech impairment predominated, reflecting the predilection for stenosis of the anterior cerebral circulation (anterior and middle cerebral artery territories). In this series, 20 percent of children had recurrent symptoms in the median 13-month follow-up interval.</p><p>Multiple recurrent events are common in other studies as well, likely reflecting the fixed stenosis susceptible to recurrent hypoperfusion. In one study from Korea of 88 children and adults who were followed for 6 to 216 months, multiple cerebrovascular events occurred in 55 percent [<a href="#rid141">141</a>]. Recurrences were most commonly ischemic.</p><p class="headingAnchor" id="H896785094"><span class="h2">Intracerebral, intraventricular, and subarachnoid hemorrhage</span><span class="headingEndMark"> — </span>While ischemic symptoms may be more common at presentation, hemorrhagic complications of moyamoya, mainly intracerebral hemorrhage (ICH), represent a significant clinical burden.</p><p>ICH is more common in adults than children [<a href="#rid138">138,142</a>]. In the International Pediatric Stroke Study, ICH was the presenting syndrome in 2.5 percent [<a href="#rid134">134</a>], while, in a series of adult patients, 10 percent of patients presented with intracranial hematoma [<a href="#rid137">137</a>].</p><p>In a systematic review, intracerebral hemorrhage at initial presentation was more frequent for patients in China and Taiwan than in the United States [<a href="#rid135">135</a>].</p><p>Intraventricular hemorrhage with or without ICH was a common presentation of MMD, according to one report from Korea [<a href="#rid143">143</a>]. In adults who presented with ICH or intraventricular hemorrhage, small aneurysms in the periventricular area have been reported  (<a class="graphic graphic_diagnosticimage graphicRef64850" href="/z/d/graphic/64850.html" rel="external">image 4</a>). Patients may also present with subarachnoid hemorrhage [<a href="#rid144">144</a>].</p><p class="headingAnchor" id="H3700179983"><span class="h2">Seizures</span><span class="headingEndMark"> — </span>Patients with moyamoya present infrequently with seizures, often secondary to ischemic damage [<a href="#rid145">145</a>]. The rate of epilepsy may be higher in children than in adults, up to 40 percent in some series [<a href="#rid142">142,146</a>].</p><p class="headingAnchor" id="H3396374938"><span class="h2">Other manifestations</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Headache</strong> – Headache is common in patients with moyamoya [<a href="#rid147">147</a>]. Migraine is the most common headache phenotype, but tension-type headache and cluster headache have also been reported [<a href="#rid148">148,149</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other neurologic symptoms</strong> – There are case reports of patients with moyamoya who develop dystonia, chorea, or dyskinesia, but these appear to be uncommon manifestations [<a href="#rid150">150-152</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Asymptomatic disease</strong> – Moyamoya can be found incidentally in asymptomatic patients undergoing screening imaging for other conditions or because of family history [<a href="#rid153">153,154</a>]. A nationwide study in Japan using a questionnaire in 1994 identified 33 asymptomatic cases (1.5 percent) out of a total of 2193 patients [<a href="#rid155">155</a>].</p><p></p><p class="headingAnchor" id="H1284385661"><span class="h1">INITIAL TEST FINDINGS</span><span class="headingEndMark"> — </span>Because patients with MMD or MMS may present with signs and symptoms of acute cerebrovascular disease, initial testing typically includes neuroimaging. Electroencephalography is often performed in patients with seizures and sometimes in those with transient ischemic attack (TIA). Specific findings on these tests may suggest moyamoya.</p><p class="headingAnchor" id="H111487920"><span class="h2">Neuroimaging</span><span class="headingEndMark"> — </span>Cerebral infarction may involve cortical and subcortical regions  (<a class="graphic graphic_diagnosticimage graphicRef74421" href="/z/d/graphic/74421.html" rel="external">image 5</a>). Ischemic injury distal to the stenotic or occluded moyamoya vessel is common in superficial and deep border-zone regions most susceptible to hypoperfusion [<a href="#rid156">156</a>]. Patterns of infarction may be suggestive of moyamoya, but these features are not specific for this condition. In a retrospective series of 32 adults with first-ever ischemic stroke, patients with early-stage MMD had ischemic lesions involving only deep subcortical structures, while those with advanced stage had predominantly cortical lesions [<a href="#rid157">157</a>].</p><p>In patients with intracerebral hemorrhage (ICH), bleeding occurs in deep structures such as the basal ganglia, thalamus, and/or ventricular system. Bleeding in the cortical and subcortical regions has been reported with lower frequency [<a href="#rid158">158,159</a>]. Asymptomatic cerebral microbleeds were present on T2*-weighted gradient-echo magnetic resonance imaging (MRI) in 30 percent or more of adult patients with MMD [<a href="#rid160">160-162</a>]. One study of 50 patients with moyamoya found that the presence of multiple microbleeds was an independent risk factor for subsequent intracerebral hemorrhage (hazard ratio [HR] 2.89, 95% CI 1.001-13.24) [<a href="#rid161">161</a>].</p><p>Additional MRI findings have been implicated in identifying vascular changes consistent with moyamoya:</p><p class="bulletIndent1"><span class="glyph">●</span>Dilated collateral vessels in the basal ganglia or thalamus can be demonstrated as multiple punctate flow voids, a finding that is considered virtually diagnostic of moyamoya  (<a class="graphic graphic_diagnosticimage graphicRef129104" href="/z/d/graphic/129104.html" rel="external">image 6</a>) [<a href="#rid163">163</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The "ivy sign" refers to focal, tubular, or serpentine hyperintensities on fluid-attenuated inversion recovery (FLAIR) or contrast-enhanced T1 images in the subarachnoid spaces that represent slow, retrograde collateral flow through engorged pial vessels via leptomeningeal anastomoses  (<a class="graphic graphic_diagnosticimage graphicRef129105" href="/z/d/graphic/129105.html" rel="external">image 7</a>) [<a href="#rid164">164-166</a>]. Observational data of 48 patients with ischemic symptoms and MMD showed the extent of the ivy sign was associated with a reduction in cerebral vascular reserve assessed by single-photon emission computed tomography (SPECT) [<a href="#rid167">167</a>]. This sign is not specific for MMS/MMD and has been reported in association with large-vessel stenosis or occlusions, where it is referred to as FLAIR vascular hyperintensities or the hyperintense vessel sign [<a href="#rid168">168</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The "brush sign" refers to prominent hypointensity in medullary veins draining areas of impaired cerebral perfusion on susceptibility-weighted imaging (SWI), a high-spatial-resolution 3D gradient-echo MRI technique that accentuates paramagnetic properties of blood products such as deoxyhemoglobin. In a group of 33 patients, the brush sign was identified more often in moyamoya patients with TIA and infarction than in asymptomatic patients. This sign was also more prominent in those with impaired cerebrovascular reserve  (<a class="graphic graphic_diagnosticimage graphicRef129106" href="/z/d/graphic/129106.html" rel="external">image 8</a>) [<a href="#rid169">169</a>]<em>. </em>Like the ivy sign, the "brush sign" is not specific for moyamoya and has been identified in patients with subacute stroke from many causes [<a href="#rid170">170</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Post-contrast enhancement within the arterial wall may be seen using high-resolution MRI [<a href="#rid171">171</a>]. One study of 24 patients with moyamoya who underwent high-resolution vessel wall imaging protocol with 3-tesla MRI showed that patients with MMD demonstrated concentric enhancement of the distal internal carotid arteries, whereas patients with intracranial atherosclerotic disease generally had focal and eccentric enhancement of the symptomatic arterial segment [<a href="#rid172">172</a>]. In addition, at six-month follow-up, vessel wall enhancement was found in eight of the nine patients (odds ratio [OR] 36.2, 95% CI 2.8-475.0), while absence of enhancement was associated with nonprogressive stenosis. This technique may be helpful if angiographic findings on other more routine testing are not diagnostic but may not be readily available in many centers.</p><p></p><p class="headingAnchor" id="H1577402342"><span class="h2">Electroencephalographic findings</span><span class="headingEndMark"> — </span>Children with MMD often exhibit abnormalities on electroencephalography (EEG).</p><p>Hyperventilation, performed as a part of EEG protocol, induces generalized high-voltage slow waves (the "build-up" phenomenon) that resolve after hyperventilation stops. The reappearance of generalized or localized high-voltage slow waves on EEG 20 to 60 seconds after the end of hyperventilation (the "rebuild-up" phenomenon) is considered pathognomonic for moyamoya and occurs in approximately two-thirds of affected children [<a href="#rid173">173,174</a>].</p><p>Asymmetric posterior alpha activity and centrotemporal slowing have also been described in children with moyamoya. Background abnormalities in children and adults with MMD include nonspecific generalized, asymmetric, or localized slow-wave activity [<a href="#rid174">174,175</a>].</p><p>Of note, hyperventilation should be minimized in patients with a diagnosis of moyamoya since it may induce reflex cerebral vasoconstriction [<a href="#rid176">176</a>]. While EEG with hyperventilation was reported to be safe in one series of 127 children [<a href="#rid174">174</a>], rare reports link hyperventilation to limb-shaking TIA and episodes of chorea and dystonia [<a href="#rid177">177-179</a>].</p><p class="headingAnchor" id="H18"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of moyamoya is made by identifying the characteristic angiographic appearance of bilateral stenoses affecting the distal internal carotid arteries (or other proximal circle of Willis vessels) along with the presence of prominent collateral vessels  (<a class="graphic graphic_diagnosticimage graphicRef74421" href="/z/d/graphic/74421.html" rel="external">image 5</a>). MMS is diagnosed by identifying characteristic angiographic features in the setting of an associated condition. MMD is diagnosed in patients with a genetic susceptibility or family history of moyamoya after associated conditions have been excluded. (See <a class="local">'Associated conditions'</a> above.)</p><p class="headingAnchor" id="H222871517"><span class="h2">Indications for vascular imaging</span><span class="headingEndMark"> — </span>The possibility of MMD disease should be considered in:</p><p class="bulletIndent1"><span class="glyph">●</span>Children or young adults with repeated symptoms of ischemic attacks resulting from low perfusion in the same arterial territory.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients who lack common factors for primary intracerebral hemorrhage (ICH) but present with intracerebral hemorrhage in brain regions supplied by small vessels that branch from the circle of Willis (eg, caudate, thalamus, or intraventricular hemorrhage within the lateral ventricles)  (<a class="graphic graphic_diagnosticimage graphicRef132277" href="/z/d/graphic/132277.html" rel="external">image 9</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Children or young adults with ischemic or hemorrhagic stroke who may lack common cerebrovascular risk factors. (See  <a class="medical medical_review" href="/z/d/html/6214.html" rel="external">"Ischemic stroke in children: Clinical presentation, evaluation, and diagnosis", section on 'Differential diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients who undergo MRI, particularly in the context of evaluation for cerebral ischemia, that shows associated findings such as dilated collateral vessels in the basal ganglia or thalamus, the "ivy sign," the "brush sign," or enhancement of the arterial wall. (See <a class="local">'Neuroimaging'</a> above.)</p><p></p><p class="headingAnchor" id="H19"><span class="h2">Diagnostic criteria</span><span class="headingEndMark"> — </span>Definitive diagnosis of moyamoya requires neurovascular imaging. Diagnostic criteria proposed by a Japanese research committee include the following major requirements [<a href="#rid4">4</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Stenosis or occlusion at the terminal portion of the internal carotid artery and at the proximal portion of the anterior and middle cerebral arteries.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Abnormal vascular networks in the basal ganglia; these networks can also be diagnosed by the presence of multiple flow voids on brain MRI.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Angiographic findings are present bilaterally; cases with unilateral angiographic findings are considered probable.</p><p></p><p>For the diagnosis of MMD, underlying associated conditions (suggestive instead of MMS) are excluded. (See <a class="local">'Further evaluation'</a> below.)</p><p class="headingAnchor" id="H3260167260"><span class="h2">Angiography</span><span class="headingEndMark"> — </span>Stenotic distal internal carotid or proximal circle of Willis arteries and prominent collateral vessels can be identified by angiogram, computed tomography angiogram (CTA), or magnetic resonance angiography (MRA). Conventional digital subtraction angiography (DSA) is the gold standard for the diagnosis of MMD. Additionally, DSA is typically required for treatment planning.</p><p>Characteristic angiographic findings include stenosis or occlusion at the distal internal carotid artery and the origin of the anterior cerebral and middle cerebral arteries on both sides, as well as abnormal vascular networks at the basal ganglia or moyamoya vessels  (<a class="graphic graphic_diagnosticimage graphicRef129102" href="/z/d/graphic/129102.html" rel="external">image 1</a>).</p><p>Noninvasive imaging (CTA and MRA) can demonstrate stenotic or occlusive lesions in the distal internal carotid arteries  (<a class="graphic graphic_diagnosticimage graphicRef51947" href="/z/d/graphic/51947.html" rel="external">image 10</a>) and the arteries around the circle of Willis [<a href="#rid180">180-182</a>]. Although less sensitive than DSA for smaller vessels, noninvasive testing can also visualize the collateral "moyamoya vessels" in the basal ganglia  (<a class="graphic graphic_diagnosticimage graphicRef129107" href="/z/d/graphic/129107.html" rel="external">image 11</a>). Nevertheless, due to its high diagnostic yield and noninvasive nature, CTA and MRA have supplanted conventional DSA in many centers as the initial imaging modality to evaluate moyamoya [<a href="#rid163">163,182</a>].</p><p>Because the vascular changes and associated risks of ischemia or hemorrhage sequelae in MMD and MMS are often progressive, characterizing the degree of vascular abnormality is important. (See  <a class="medical medical_review" href="/z/d/html/1112.html" rel="external">"Moyamoya disease and moyamoya syndrome: Treatment and prognosis", section on 'Neuroimaging'</a>.)</p><p>Angiographic severity staging systems can provide insight and guidance. Suzuki followed patients with MMD and classified the angiographic progression [<a href="#rid183">183,184</a>].</p><p class="headingAnchor" id="H1070085372"><span class="h2">Further evaluation</span><span class="headingEndMark"> — </span>In the absence of a known genetic predisposition to MMD or known diagnosis associated with MMS (eg, sickle cell anemia), patients should be further evaluated for underlying conditions in order to institute the most appropriate secondary prevention strategy. Evaluation for vasculitis and other metabolic conditions may be indicated when suggestive features of clinical presentation are present. In general, work-up for atherosclerotic risk factors such as diabetes, dyslipidemia, hyperhomocysteinemia, and alternative sources to large-vessel vasculopathy should be performed. (See  <a class="medical medical_review" href="/z/d/html/8230.html" rel="external">"Primary angiitis of the central nervous system in adults", section on 'When to suspect the diagnosis'</a> and  <a class="medical medical_review" href="/z/d/html/131456.html" rel="external">"Intracranial large artery atherosclerosis: Epidemiology, clinical manifestations, and diagnosis", section on 'Identifying other causes of intracranial stenosis'</a>.)</p><p>Hemodynamic studies are useful both pre- and postoperatively to help determine cerebrovascular reserve and to assess disease severity and risk of ischemic morbidity. These topics are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1112.html" rel="external">"Moyamoya disease and moyamoya syndrome: Treatment and prognosis", section on 'Neuroimaging'</a>.)</p><p class="headingAnchor" id="H20"><span class="h1">SCREENING IMAGING</span><span class="headingEndMark"> — </span>In general, we do not screen asymptomatic individuals for moyamoya; however, screening with a noninvasive angiographic modality may be reasonable in those with a family history of MMD, particularly individuals from or with families from Eastern Asia.</p><p>The 2008 American Heart Association Stroke Council guidelines state that there is insufficient evidence to justify screening studies in asymptomatic individuals or in relatives of patients with MMS in the absence of a strong family history of MMD or medical conditions that predispose to MMS [<a href="#rid163">163</a>].</p><p>Even in individuals with a strong family history of MMD or those with medical conditions that predispose to MMS, the utility of angiographic screening is unclear, particularly since available medical and surgical treatment of asymptomatic MMD is of uncertain benefit.</p><p class="headingAnchor" id="H3562723157"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/105370.html" rel="external">"Society guideline links: Stroke in adults"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/112685.html" rel="external">"Society guideline links: Stroke in children"</a>.)</p><p class="headingAnchor" id="H21"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Classification and terminology</strong> – Moyamoya describes chronic progressive cerebrovascular diseases typically characterized by bilateral stenosis or occlusion of the arteries around the circle of Willis with prominent arterial collateral circulation. (See <a class="local">'Classification and terminology'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Moyamoya disease (MMD) refers to patients with moyamoya angiographic findings who may have genetic susceptibilities but no underlying risk factors.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Moyamoya syndrome (MMS) refers to patients with moyamoya angiographic findings who also have an associated medical condition. (See <a class="local">'Classification and terminology'</a> above and <a class="local">'Associated conditions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – MMD and MMS are rare. MMD is more common in East Asian countries than elsewhere. There is a bimodal distribution in the age of onset, with one peak at approximately 10 years of age and a second, broader peak at approximately 40 years of age. (See <a class="local">'Incidence and prevalence'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentations</strong> – Ischemic stroke and transient ischemic attack (TIA) affecting the anterior circulation are the most common clinical presentations. (See <a class="local">'Ischemic stroke and transient ischemic attack'</a> above and <a class="local">'Neuroimaging'</a> above.)</p><p></p><p class="bulletIndent1">Intracranial hemorrhage is less common and is rare in children. Hemorrhage usually affects deep structures such as the basal ganglia or thalamus but may also be intraventricular or subarachnoid. (See <a class="local">'Intracerebral, intraventricular, and subarachnoid hemorrhage'</a> above and <a class="local">'Neuroimaging'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical and imaging findings suggestive of underlying moyamoya pathology</strong> – MRI findings that suggest the diagnosis of moyamoya include dilated collateral vessels in the basal ganglia or thalamus, the "ivy sign," or the "brush sign." (See <a class="local">'Neuroimaging'</a> above.)</p><p></p><p class="bulletIndent1">The diagnosis of moyamoya is most often considered in those with suggestive MRI findings in the context of evaluation for ischemic stroke. Other settings in which the diagnosis should be considered include repeated episodes of ischemia in the same arterial territory, deep intracerebral hemorrhage in the absence of hypertension or other known cause, and ischemic or hemorrhagic stroke in children or young adults who lack cerebrovascular risk factors. (See <a class="local">'Indications for vascular imaging'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of moyamoya is made by angiographic demonstration of bilateral stenoses affecting the distal internal carotid arteries or proximal circle of Willis vessels along with the presence of prominent basal collateral vessels. (See <a class="local">'Diagnosis'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Smith ER, Scott RM. Spontaneous occlusion of the circle of Willis in children: pediatric moyamoya summary with proposed evidence-based practice guidelines. A review. J Neurosurg Pediatr 2012; 9:353.</a></li><li><a class="nounderline abstract_t">Fukui M. Guidelines for the diagnosis and treatment of spontaneous occlusion of the circle of Willis ('moyamoya' disease). Research Committee on Spontaneous Occlusion of the Circle of Willis (Moyamoya Disease) of the Ministry of Health and Welfare, Japan. Clin Neurol Neurosurg 1997; 99 Suppl 2:S238.</a></li><li><a class="nounderline abstract_t">Arias EJ, Derdeyn CP, Dacey RG Jr, Zipfel GJ. Advances and surgical considerations in the treatment of moyamoya disease. Neurosurgery 2014; 74 Suppl 1:S116.</a></li><li><a class="nounderline abstract_t">Research Committee on the Pathology and Treatment of Spontaneous Occlusion of the Circle of Willis, Health Labour Sciences Research Grant for Research on Measures for Infractable Diseases. Guidelines for diagnosis and treatment of moyamoya disease (spontaneous occlusion of the circle of Willis). Neurol Med Chir (Tokyo) 2012; 52:245.</a></li><li class="breakAll">Kim JS, Bang OY, Oh CW. Moyamoya disease. In: Uncommon Causes of Stroke, 3rd ed, Caplan L, Biller J (Eds), Cambridge University Press, New York, NY 2018. p.545.</li><li><a class="nounderline abstract_t">Kamada F, Aoki Y, Narisawa A, et al. A genome-wide association study identifies RNF213 as the first Moyamoya disease gene. J Hum Genet 2011; 56:34.</a></li><li><a class="nounderline abstract_t">Liu W, Morito D, Takashima S, et al. Identification of RNF213 as a susceptibility gene for moyamoya disease and its possible role in vascular development. PLoS One 2011; 6:e22542.</a></li><li><a class="nounderline abstract_t">Miyatake S, Miyake N, Touho H, et al. Homozygous c.14576G&gt;A variant of RNF213 predicts early-onset and severe form of moyamoya disease. Neurology 2012; 78:803.</a></li><li><a class="nounderline abstract_t">Yamauchi T, Tada M, Houkin K, et al. Linkage of familial moyamoya disease (spontaneous occlusion of the circle of Willis) to chromosome 17q25. Stroke 2000; 31:930.</a></li><li><a class="nounderline abstract_t">Mineharu Y, Liu W, Inoue K, et al. Autosomal dominant moyamoya disease maps to chromosome 17q25.3. Neurology 2008; 70:2357.</a></li><li><a class="nounderline abstract_t">Miyawaki S, Imai H, Takayanagi S, et al. Identification of a genetic variant common to moyamoya disease and intracranial major artery stenosis/occlusion. Stroke 2012; 43:3371.</a></li><li><a class="nounderline abstract_t">Wu Z, Jiang H, Zhang L, et al. Molecular analysis of RNF213 gene for moyamoya disease in the Chinese Han population. PLoS One 2012; 7:e48179.</a></li><li><a class="nounderline abstract_t">Bang OY, Ryoo S, Kim SJ, et al. Adult Moyamoya Disease: A Burden of Intracranial Stenosis in East Asians? PLoS One 2015; 10:e0130663.</a></li><li><a class="nounderline abstract_t">Wang Y, Zhang Z, Wei L, et al. Predictive role of heterozygous p.R4810K of RNF213 in the phenotype of Chinese moyamoya disease. Neurology 2020; 94:e678.</a></li><li><a class="nounderline abstract_t">Ikeda H, Sasaki T, Yoshimoto T, et al. Mapping of a familial moyamoya disease gene to chromosome 3p24.2-p26. Am J Hum Genet 1999; 64:533.</a></li><li><a class="nounderline abstract_t">Inoue TK, Ikezaki K, Sasazuki T, et al. Linkage analysis of moyamoya disease on chromosome 6. J Child Neurol 2000; 15:179.</a></li><li><a class="nounderline abstract_t">Sakurai K, Horiuchi Y, Ikeda H, et al. A novel susceptibility locus for moyamoya disease on chromosome 8q23. J Hum Genet 2004; 49:278.</a></li><li><a class="nounderline abstract_t">Mineharu Y, Takenaka K, Yamakawa H, et al. Inheritance pattern of familial moyamoya disease: autosomal dominant mode and genomic imprinting. J Neurol Neurosurg Psychiatry 2006; 77:1025.</a></li><li><a class="nounderline abstract_t">Duan L, Wei L, Tian Y, et al. Novel Susceptibility Loci for Moyamoya Disease Revealed by a Genome-Wide Association Study. Stroke 2018; 49:11.</a></li><li><a class="nounderline abstract_t">Lee SJ, Ahn JY. Stenosis of the proximal external carotid artery in an adult with moyamoya disease: moyamoya or atherosclerotic change? Neurol Med Chir (Tokyo) 2007; 47:356.</a></li><li><a class="nounderline abstract_t">Ullrich NJ, Robertson R, Kinnamon DD, et al. Moyamoya following cranial irradiation for primary brain tumors in children. Neurology 2007; 68:932.</a></li><li><a class="nounderline abstract_t">Fernandez-Alvarez E, Pineda M, Royo C, Manzanares R. "Moya-moya' disease caused by cranial trauma. Brain Dev 1979; 1:133.</a></li><li><a class="nounderline abstract_t">Kitano S, Sakamoto H, Fujitani K, Kobayashi Y. Moyamoya disease associated with a brain stem glioma. Childs Nerv Syst 2000; 16:251.</a></li><li><a class="nounderline abstract_t">Arita K, Uozumi T, Oki S, et al. Moyamoya disease associated with pituitary adenoma--report of two cases. Neurol Med Chir (Tokyo) 1992; 32:753.</a></li><li><a class="nounderline abstract_t">Tsuji N, Kuriyama T, Iwamoto M, Shizuki K. Moyamoya disease associated with craniopharyngioma. Surg Neurol 1984; 21:588.</a></li><li><a class="nounderline abstract_t">Czartoski T, Hallam D, Lacy JM, et al. Postinfectious vasculopathy with evolution to moyamoya syndrome. J Neurol Neurosurg Psychiatry 2005; 76:256.</a></li><li><a class="nounderline abstract_t">Yamada H, Deguchi K, Tanigawara T, et al. The relationship between moyamoya disease and bacterial infection. Clin Neurol Neurosurg 1997; 99 Suppl 2:S221.</a></li><li><a class="nounderline abstract_t">Sharfstein SR, Ahmed S, Islam MQ, et al. Case of moyamoya disease in a patient with advanced acquired immunodeficiency syndrome. J Stroke Cerebrovasc Dis 2007; 16:268.</a></li><li><a class="nounderline abstract_t">Hammond CK, Shapson-Coe A, Govender R, et al. Moyamoya Syndrome in South African Children With HIV-1 Infection. J Child Neurol 2016; 31:1010.</a></li><li><a class="nounderline abstract_t">Fryer RH, Anderson RC, Chiriboga CA, Feldstein NA. Sickle cell anemia with moyamoya disease: outcomes after EDAS procedure. Pediatr Neurol 2003; 29:124.</a></li><li><a class="nounderline abstract_t">Dobson SR, Holden KR, Nietert PJ, et al. Moyamoya syndrome in childhood sickle cell disease: a predictive factor for recurrent cerebrovascular events. Blood 2002; 99:3144.</a></li><li><a class="nounderline abstract_t">Kirkham FJ, DeBaun MR. Stroke in Children with Sickle Cell Disease. Curr Treat Options Neurol 2004; 6:357.</a></li><li><a class="nounderline abstract_t">Marden FA, Putman CM, Grant JM, Greenberg J. Moyamoya disease associated with hemoglobin Fairfax and beta-thalassemia. Pediatr Neurol 2008; 38:130.</a></li><li><a class="nounderline abstract_t">Pavlakis SG, Verlander PC, Gould RJ, et al. Fanconi anemia and moyamoya: evidence for an association. Neurology 1995; 45:998.</a></li><li><a class="nounderline abstract_t">Tokunaga Y, Ohga S, Suita S, et al. Moyamoya syndrome with spherocytosis: effect of splenectomy on strokes. Pediatr Neurol 2001; 25:75.</a></li><li><a class="nounderline abstract_t">Cerrato P, Grasso M, Lentini A, et al. Atherosclerotic adult Moya-Moya disease in a patient with hyperhomocysteinaemia. Neurol Sci 2007; 28:45.</a></li><li><a class="nounderline abstract_t">Dhopesh VP, Dunn DP, Schick P. Moyamoya and Hageman factor (Factor XII) deficiency in a black adult. Arch Neurol 1978; 35:396.</a></li><li><a class="nounderline abstract_t">Kornblihtt LI, Cocorullo S, Miranda C, et al. Moyamoya syndrome in an adolescent with essential thrombocythemia: successful intracranial carotid stent placement. Stroke 2005; 36:E71.</a></li><li><a class="nounderline abstract_t">Cheong PL, Lee WT, Liu HM, Lin KH. Moyamoya syndrome with inherited proteins C and S deficiency: report of one case. Acta Paediatr Taiwan 2005; 46:31.</a></li><li><a class="nounderline abstract_t">Charuvanij A, Laothamatas J, Torcharus K, Sirivimonmas S. Moyamoya disease and protein S deficiency: a case report. Pediatr Neurol 1997; 17:171.</a></li><li><a class="nounderline abstract_t">Cevik B, Acu B, Aksoy D, Kurt S. Protein S Deficiency and an Adult Case with Moyamoya Syndrome that Presented with Primary Intraventricular Haemorrhage. Balkan Med J 2014; 31:180.</a></li><li><a class="nounderline abstract_t">Skardoutsou A, Voudris KA, Mastroyianni S, et al. Moya moya syndrome in a child with pyruvate kinase deficiency and combined prothrombotic factors. J Child Neurol 2007; 22:474.</a></li><li><a class="nounderline abstract_t">Wang R, Xu Y, Lv R, Chen J. Systemic lupus erythematosus associated with Moyamoya syndrome: a case report and literature review. Lupus 2013; 22:629.</a></li><li><a class="nounderline abstract_t">Kendall B. Cerebral angiography in vasculitis affecting the nervous system. Eur Neurol 1984; 23:400.</a></li><li><a class="nounderline abstract_t">Sasaki T, Nogawa S, Amano T. Co-morbidity of moyamoya disease with Graves' disease. report of three cases and a review of the literature. Intern Med 2006; 45:649.</a></li><li><a class="nounderline abstract_t">Im SH, Oh CW, Kwon OK, et al. Moyamoya disease associated with Graves disease: special considerations regarding clinical significance and management. J Neurosurg 2005; 102:1013.</a></li><li><a class="nounderline abstract_t">Kushima K, Satoh Y, Ban Y, et al. Graves' thyrotoxicosis and Moyamoya disease. Can J Neurol Sci 1991; 18:140.</a></li><li><a class="nounderline abstract_t">Bower RS, Mallory GW, Nwojo M, et al. Moyamoya disease in a primarily white, midwestern US population: increased prevalence of autoimmune disease. Stroke 2013; 44:1997.</a></li><li><a class="nounderline abstract_t">Carhuapoma JR, D'Olhaberriague L, Levine SR. Moyamoya syndrome associated with Sneddon's syndrome and antiphospholipid-protein antibodies. J Stroke Cerebrovasc Dis 1999; 8:51.</a></li><li><a class="nounderline abstract_t">Bonduel M, Hepner M, Sciuccati G, et al. Prothrombotic disorders in children with moyamoya syndrome. Stroke 2001; 32:1786.</a></li><li><a class="nounderline abstract_t">Provost TT, Moses H, Morris EL, et al. Cerebral vasculopathy associated with collateralization resembling moya moya phenomenon and with anti-Ro/SS-A and anti-La/SS-B antibodies. Arthritis Rheum 1991; 34:1052.</a></li><li><a class="nounderline abstract_t">Kim JS, No YJ. Moyamoya-like vascular abnormality in pulmonary sarcoidosis. Cerebrovasc Dis 2006; 22:71.</a></li><li><a class="nounderline abstract_t">Takenaka K, Ito M, Kumagai M, et al. Moyamoya disease associated with pulmonary sarcoidosis--case report. Neurol Med Chir (Tokyo) 1998; 38:566.</a></li><li><a class="nounderline abstract_t">Kamath BM, Spinner NB, Emerick KM, et al. Vascular anomalies in Alagille syndrome: a significant cause of morbidity and mortality. Circulation 2004; 109:1354.</a></li><li><a class="nounderline abstract_t">Rocha R, Soro I, Leitão A, et al. Moyamoya vascular pattern in Alagille syndrome. Pediatr Neurol 2012; 47:125.</a></li><li><a class="nounderline abstract_t">Jea A, Smith ER, Robertson R, Scott RM. Moyamoya syndrome associated with Down syndrome: outcome after surgical revascularization. Pediatrics 2005; 116:e694.</a></li><li><a class="nounderline abstract_t">de Borchgrave V, Saussu F, Depre A, de Barsy T. Moyamoya disease and Down syndrome: case report and review of the literature. Acta Neurol Belg 2002; 102:63.</a></li><li><a class="nounderline abstract_t">Rafay MF, Al-Futaisi A, Weiss S, Armstrong D. Hypomelanosis of Ito and Moyamoya disease. J Child Neurol 2005; 20:924.</a></li><li><a class="nounderline abstract_t">Terada T, Yokote H, Tsuura M, et al. Marfan syndrome associated with moyamoya phenomenon and aortic dissection. Acta Neurochir (Wien) 1999; 141:663.</a></li><li><a class="nounderline abstract_t">Teo M, Johnson JN, Bell-Stephens TE, et al. Surgical outcomes of Majewski osteodysplastic primordial dwarfism Type II with intracranial vascular anomalies. J Neurosurg Pediatr 2016; 25:717.</a></li><li><a class="nounderline abstract_t">Hervé D, Touraine P, Verloes A, et al. A hereditary moyamoya syndrome with multisystemic manifestations. Neurology 2010; 75:259.</a></li><li><a class="nounderline abstract_t">Miskinyte S, Butler MG, Hervé D, et al. Loss of BRCC3 deubiquitinating enzyme leads to abnormal angiogenesis and is associated with syndromic moyamoya. Am J Hum Genet 2011; 88:718.</a></li><li><a class="nounderline abstract_t">Khan M, Novakovic RL, Rosengart AJ. Intraventricular hemorrhage disclosing neurofibromatosis 1 and moyamoya phenomena. Arch Neurol 2006; 63:1653.</a></li><li><a class="nounderline abstract_t">Horikawa M, Utunomiya H, Hirotaka S, et al. Case of von Recklinghausen disease associated with cerebral infarction. J Child Neurol 1997; 12:144.</a></li><li><a class="nounderline abstract_t">Rosser TL, Vezina G, Packer RJ. Cerebrovascular abnormalities in a population of children with neurofibromatosis type 1. Neurology 2005; 64:553.</a></li><li><a class="nounderline abstract_t">Brosius SN, Vossough A, Fisher MJ, et al. Characteristics of Moyamoya Syndrome in Pediatric Patients With Neurofibromatosis Type 1. Pediatr Neurol 2022; 134:85.</a></li><li><a class="nounderline abstract_t">Gupta M, Choudhri OA, Feroze AH, et al. Management of moyamoya syndrome in patients with Noonan syndrome. J Clin Neurosci 2016; 28:107.</a></li><li><a class="nounderline abstract_t">Hung PC, Wang HS, Wong AM. Moyamoya syndrome in a child with Noonan syndrome. Pediatr Neurol 2011; 45:129.</a></li><li><a class="nounderline abstract_t">Ganesan V, Kirkham FJ. Noonan syndrome and moyamoya. Pediatr Neurol 1997; 16:256.</a></li><li><a class="nounderline abstract_t">Tsuruta D, Fukai K, Seto M, et al. Phakomatosis pigmentovascularis type IIIb associated with moyamoya disease. Pediatr Dermatol 1999; 16:35.</a></li><li><a class="nounderline abstract_t">Kusuhara T, Ayabe M, Hino H, et al. [A case of Prader-Willi syndrome with bilateral middle cerebral artery occlusion and moyamoya phenomenon]. Rinsho Shinkeigaku 1996; 36:770.</a></li><li><a class="nounderline abstract_t">Meyer S, Zanardo L, Kaminski WE, et al. Elastosis perforans serpiginosa-like pseudoxanthoma elasticum in a child with severe Moya Moya disease. Br J Dermatol 2005; 153:431.</a></li><li><a class="nounderline abstract_t">Garcia JC, Roach ES, McLean WT. Recurrent thrombotic deterioration in the Sturge-Weber syndrome. Childs Brain 1981; 8:427.</a></li><li><a class="nounderline abstract_t">Imaizumi M, Nukada T, Yoneda S, et al. Tuberous sclerosis with moyamoya disease. Case report. Med J Osaka Univ 1978; 28:345.</a></li><li><a class="nounderline abstract_t">Spengos K, Kosmaidou-Aravidou Z, Tsivgoulis G, et al. Moyamoya syndrome in a Caucasian woman with Turner's syndrome. Eur J Neurol 2006; 13:e7.</a></li><li><a class="nounderline abstract_t">Kawai M, Nishikawa T, Tanaka M, et al. An autopsied case of Williams syndrome complicated by moyamoya disease. Acta Paediatr Jpn 1993; 35:63.</a></li><li><a class="nounderline abstract_t">Quah BL, Hamilton J, Blaser S, et al. Morning glory disc anomaly, midline cranial defects and abnormal carotid circulation: an association worth looking for. Pediatr Radiol 2005; 35:525.</a></li><li><a class="nounderline abstract_t">Komiyama M, Yasui T, Sakamoto H, et al. Basal meningoencephalocele, anomaly of optic disc and panhypopituitarism in association with moyamoya disease. Pediatr Neurosurg 2000; 33:100.</a></li><li><a class="nounderline abstract_t">Krishnan C, Roy A, Traboulsi E. Morning glory disk anomaly, choroidal coloboma, and congenital constrictive malformations of the internal carotid arteries (moyamoya disease). Ophthalmic Genet 2000; 21:21.</a></li><li><a class="nounderline abstract_t">Christiaens FJ, Van den Broeck LK, Christophe C, Dan B. Moyamoya disease (moyamoya syndrome) and coarctation of the aorta. Neuropediatrics 2000; 31:47.</a></li><li><a class="nounderline abstract_t">Lutterman J, Scott M, Nass R, Geva T. Moyamoya syndrome associated with congenital heart disease. Pediatrics 1998; 101:57.</a></li><li><a class="nounderline abstract_t">de Vries RR, Nikkels PG, van der Laag J, et al. Moyamoya and extracranial vascular involvement: fibromuscular dysplasia? A report of two children. Neuropediatrics 2003; 34:318.</a></li><li><a class="nounderline abstract_t">Yamada I, Himeno Y, Matsushima Y, Shibuya H. Renal artery lesions in patients with moyamoya disease: angiographic findings. Stroke 2000; 31:733.</a></li><li><a class="nounderline abstract_t">Sunder TR. Moyamoya disease in a patient with type I glycogenosis. Arch Neurol 1981; 38:251.</a></li><li><a class="nounderline abstract_t">Goutières F, Bourgeois M, Trioche P, et al. Moyamoya disease in a child with glycogen storage disease type Ia. Neuropediatrics 1997; 28:133.</a></li><li><a class="nounderline abstract_t">Tokuç G, Minareci O, Yavuzer D, et al. Moya Moya syndrome in a child with hyperphosphatasia. Pediatr Int 1999; 41:399.</a></li><li><a class="nounderline abstract_t">Lammie GA, Wardlaw J, Dennis M. Thrombo-embolic stroke, moya-moya phenomenon and primary oxalosis. Cerebrovasc Dis 1998; 8:45.</a></li><li><a class="nounderline abstract_t">Pracyk JB, Massey JM. Moyamoya disease associated with polycystic kidney disease and eosinophilic granuloma. Stroke 1989; 20:1092.</a></li><li><a class="nounderline abstract_t">Nzwalo H, Santos V, Gradil C, et al. Caucasian familial moyamoya syndrome with rare multisystemic malformations. Pediatr Neurol 2013; 48:240.</a></li><li><a class="nounderline abstract_t">Peerless SJ. Risk factors of moyamoya disease in Canada and the USA. Clin Neurol Neurosurg 1997; 99 Suppl 2:S45.</a></li><li><a class="nounderline abstract_t">Hosoda Y. Pathology of so-called "spontaneous occlusion of the circle of Willis". Pathol Annu 1984; 19 Pt 2:221.</a></li><li><a class="nounderline abstract_t">Goldstein M, Hanquinet P, Couvreur Y. [A case of fibromuscular dysplasia in an unusual location]. Acta Chir Belg 1984; 84:345.</a></li><li><a class="nounderline abstract_t">Oka K, Yamashita M, Sadoshima S, Tanaka K. Cerebral haemorrhage in Moyamoya disease at autopsy. Virchows Arch A Pathol Anat Histol 1981; 392:247.</a></li><li><a class="nounderline abstract_t">Carlson CB, Harvey FH, Loop J. Progressive alternating hemiplegia in early childhood and basal arterial stenosis and telangiectasia (moyamoya syndrome). Neurology 1973; 23:734.</a></li><li><a class="nounderline abstract_t">Kodama N, Fujiwara S, Horie Y, et al. [Transdural anastomosis in moyamoya disease--vault moyamoy (author's transl)]. No Shinkei Geka 1980; 8:729.</a></li><li><a class="nounderline abstract_t">Kodama N, Suzuki J. Moyamoya disease associated with aneurysm. J Neurosurg 1978; 48:565.</a></li><li><a class="nounderline abstract_t">Adams HP Jr, Kassell NF, Wisoff HS, Drake CG. Intracranial saccular aneurysm and moyamoya disease. Stroke 1979; 10:174.</a></li><li><a class="nounderline abstract_t">Nagamine Y, Takahashi S, Sonobe M. Multiple intracranial aneurysms associated with moyamoya disease. Case report. J Neurosurg 1981; 54:673.</a></li><li><a class="nounderline abstract_t">Yabumoto M, Funahashi K, Fujii T, et al. Moyamoya disease associated with intracranial aneurysms. Surg Neurol 1983; 20:20.</a></li><li><a class="nounderline abstract_t">Konishi Y, Kadowaki C, Hara M, Takeuchi K. Aneurysms associated with moyamoya disease. Neurosurgery 1985; 16:484.</a></li><li><a class="nounderline abstract_t">Herreman F, Nathal E, Yasui N, et al. Intracranial aneurysm in moyamoya disease: report of ten cases and review of the literature. Cerebrovasc Dis 1994; 4:329.</a></li><li><a class="nounderline abstract_t">Ikeda E. Systemic vascular changes in spontaneous occlusion of the circle of Willis. Stroke 1991; 22:1358.</a></li><li><a class="nounderline abstract_t">Watanabe Y, Todani T, Fujii T, et al. Wilms' tumor associated with Moyamoya disease: a case report. Z Kinderchir 1985; 40:114.</a></li><li><a class="nounderline abstract_t">Ihara M, Yamamoto Y, Hattori Y, et al. Moyamoya disease: diagnosis and interventions. Lancet Neurol 2022; 21:747.</a></li><li><a class="nounderline abstract_t">Rafat N, Beck GCh, Peña-Tapia PG, et al. Increased levels of circulating endothelial progenitor cells in patients with Moyamoya disease. Stroke 2009; 40:432.</a></li><li><a class="nounderline abstract_t">Choi JW, Son SM, Mook-Jung I, et al. Mitochondrial abnormalities related to the dysfunction of circulating endothelial colony-forming cells in moyamoya disease. J Neurosurg 2018; 129:1151.</a></li><li><a class="nounderline abstract_t">Kang HS, Kim JH, Phi JH, et al. Plasma matrix metalloproteinases, cytokines and angiogenic factors in moyamoya disease. J Neurol Neurosurg Psychiatry 2010; 81:673.</a></li><li><a class="nounderline abstract_t">Suzui H, Hoshimaru M, Takahashi JA, et al. Immunohistochemical reactions for fibroblast growth factor receptor in arteries of patients with moyamoya disease. Neurosurgery 1994; 35:20.</a></li><li><a class="nounderline abstract_t">Malek AM, Connors S, Robertson RL, et al. Elevation of cerebrospinal fluid levels of basic fibroblast growth factor in moyamoya and central nervous system disorders. Pediatr Neurosurg 1997; 27:182.</a></li><li><a class="nounderline abstract_t">Yamamoto M, Aoyagi M, Tajima S, et al. Increase in elastin gene expression and protein synthesis in arterial smooth muscle cells derived from patients with Moyamoya disease. Stroke 1997; 28:1733.</a></li><li><a class="nounderline abstract_t">Hojo M, Hoshimaru M, Miyamoto S, et al. Role of transforming growth factor-beta1 in the pathogenesis of moyamoya disease. J Neurosurg 1998; 89:623.</a></li><li><a class="nounderline abstract_t">Nanba R, Kuroda S, Ishikawa T, et al. Increased expression of hepatocyte growth factor in cerebrospinal fluid and intracranial artery in moyamoya disease. Stroke 2004; 35:2837.</a></li><li><a class="nounderline abstract_t">Morgenlander JC, Goldstein LB. Recurrent transient ischemic attacks and stroke in association with an internal carotid artery web. Stroke 1991; 22:94.</a></li><li><a class="nounderline abstract_t">Guey S, Tournier-Lasserve E, Hervé D, Kossorotoff M. Moyamoya disease and syndromes: from genetics to clinical management. Appl Clin Genet 2015; 8:49.</a></li><li><a class="nounderline abstract_t">Smith ER, Scott RM. Progression of disease in unilateral moyamoya syndrome. Neurosurg Focus 2008; 24:E17.</a></li><li><a class="nounderline abstract_t">Church EW, Bell-Stephens TE, Bigder MG, et al. Clinical Course of Unilateral Moyamoya Disease. Neurosurgery 2020; 87:1262.</a></li><li><a class="nounderline abstract_t">Yamashita M, Oka K, Tanaka K. Histopathology of the brain vascular network in moyamoya disease. Stroke 1983; 14:50.</a></li><li><a class="nounderline abstract_t">Hosoda Y, Ikeda E, Hirose S. Histopathological studies on spontaneous occlusion of the circle of Willis (cerebrovascular moyamoya disease). Clin Neurol Neurosurg 1997; 99 Suppl 2:S203.</a></li><li><a class="nounderline abstract_t">Takagi Y, Kikuta K, Nozaki K, Hashimoto N. Histological features of middle cerebral arteries from patients treated for Moyamoya disease. Neurol Med Chir (Tokyo) 2007; 47:1.</a></li><li><a class="nounderline abstract_t">Kawaguchi S, Sakaki T, Morimoto T, et al. Characteristics of intracranial aneurysms associated with moyamoya disease. A review of 111 cases. Acta Neurochir (Wien) 1996; 138:1287.</a></li><li><a class="nounderline abstract_t">Togao O, Mihara F, Yoshiura T, et al. Prevalence of stenoocclusive lesions in the renal and abdominal arteries in moyamoya disease. AJR Am J Roentgenol 2004; 183:119.</a></li><li><a class="nounderline abstract_t">Goto Y, Yonekawa Y. Worldwide distribution of moyamoya disease. Neurol Med Chir (Tokyo) 1992; 32:883.</a></li><li><a class="nounderline abstract_t">Uchino K, Johnston SC, Becker KJ, Tirschwell DL. Moyamoya disease in Washington State and California. Neurology 2005; 65:956.</a></li><li><a class="nounderline abstract_t">Wakai K, Tamakoshi A, Ikezaki K, et al. Epidemiological features of moyamoya disease in Japan: findings from a nationwide survey. Clin Neurol Neurosurg 1997; 99 Suppl 2:S1.</a></li><li><a class="nounderline abstract_t">Kuriyama S, Kusaka Y, Fujimura M, et al. Prevalence and clinicoepidemiological features of moyamoya disease in Japan: findings from a nationwide epidemiological survey. Stroke 2008; 39:42.</a></li><li><a class="nounderline abstract_t">Baba T, Houkin K, Kuroda S. Novel epidemiological features of moyamoya disease. J Neurol Neurosurg Psychiatry 2008; 79:900.</a></li><li><a class="nounderline abstract_t">Sato Y, Kazumata K, Nakatani E, et al. Characteristics of Moyamoya Disease Based on National Registry Data in Japan. Stroke 2019; 50:1973.</a></li><li><a class="nounderline abstract_t">Starke RM, Crowley RW, Maltenfort M, et al. Moyamoya disorder in the United States. Neurosurgery 2012; 71:93.</a></li><li><a class="nounderline abstract_t">Hayashi K, Horie N, Izumo T, Nagata I. Nationwide survey on quasi-moyamoya disease in Japan. Acta Neurochir (Wien) 2014; 156:935.</a></li><li><a class="nounderline abstract_t">Zhao M, Lin Z, Deng X, et al. Clinical Characteristics and Natural History of Quasi-Moyamoya Disease. J Stroke Cerebrovasc Dis 2017; 26:1088.</a></li><li><a class="nounderline abstract_t">Amlie-Lefond C, Zaidat OO, Lew SM. Moyamoya disease in early infancy: case report and literature review. Pediatr Neurol 2011; 44:299.</a></li><li><a class="nounderline abstract_t">Al-Yassin A, Saunders DE, Mackay MT, Ganesan V. Early-onset bilateral cerebral arteriopathies: Cohort study of phenotype and disease course. Neurology 2015; 85:1146.</a></li><li><a class="nounderline abstract_t">Duan L, Bao XY, Yang WZ, et al. Moyamoya disease in China: its clinical features and outcomes. Stroke 2012; 43:56.</a></li><li><a class="nounderline abstract_t">Lee S, Rivkin MJ, Kirton A, et al. Moyamoya Disease in Children: Results From the International Pediatric Stroke Study. J Child Neurol 2017; 32:924.</a></li><li><a class="nounderline abstract_t">Kleinloog R, Regli L, Rinkel GJ, Klijn CJ. Regional differences in incidence and patient characteristics of moyamoya disease: a systematic review. J Neurol Neurosurg Psychiatry 2012; 83:531.</a></li><li><a class="nounderline abstract_t">Kraemer M, Heienbrok W, Berlit P. Moyamoya disease in Europeans. Stroke 2008; 39:3193.</a></li><li><a class="nounderline abstract_t">Zafar SF, Bershad EM, Gildersleeve KL, et al. Adult moyamoya disease in an urban center in the United States is associated with a high burden of watershed ischemia. J Am Heart Assoc 2014; 3.</a></li><li><a class="nounderline abstract_t">Scott RM, Smith ER. Moyamoya disease and moyamoya syndrome. N Engl J Med 2009; 360:1226.</a></li><li><a class="nounderline abstract_t">Hung CC, Tu YK, Su CF, et al. Epidemiological study of moyamoya disease in Taiwan. Clin Neurol Neurosurg 1997; 99 Suppl 2:S23.</a></li><li><a class="nounderline abstract_t">Battistella PA, Carollo C. Clinical and neuroradiological findings of moyamoya disease in Italy. Clin Neurol Neurosurg 1997; 99 Suppl 2:S54.</a></li><li><a class="nounderline abstract_t">Choi JU, Kim DS, Kim EY, Lee KC. Natural history of moyamoya disease: comparison of activity of daily living in surgery and non surgery groups. Clin Neurol Neurosurg 1997; 99 Suppl 2:S11.</a></li><li class="breakAll">Kitamura K, Fukui M, Oka K. Moyamoya disease. In: Handbook of Clinical Neurology, Elsevier, Amsterdam, 1989. Vol 2, p.293.</li><li><a class="nounderline abstract_t">Nah HW, Kwon SU, Kang DW, et al. Moyamoya disease-related versus primary intracerebral hemorrhage: [corrected] location and outcomes are different. Stroke 2012; 43:1947.</a></li><li><a class="nounderline abstract_t">Wan M, Han C, Xian P, et al. Moyamoya disease presenting with subarachnoid hemorrhage: Clinical features and neuroimaging of a case series. Br J Neurosurg 2015; 29:804.</a></li><li><a class="nounderline abstract_t">Kim JS. Moyamoya Disease: Epidemiology, Clinical Features, and Diagnosis. J Stroke 2016; 18:2.</a></li><li><a class="nounderline abstract_t">Gatti JR, Penn R, Ahmad SA, Sun LR. Seizures in Pediatric Moyamoya: Risk Factors and Functional Outcomes. Pediatr Neurol 2023; 145:36.</a></li><li><a class="nounderline abstract_t">Seol HJ, Wang KC, Kim SK, et al. Headache in pediatric moyamoya disease: review of 204 consecutive cases. J Neurosurg 2005; 103:439.</a></li><li><a class="nounderline abstract_t">Kraemer M, Lee SI, Ayzenberg I, et al. Headache in Caucasian patients with Moyamoya angiopathy - a systematic cohort study. Cephalalgia 2017; 37:496.</a></li><li><a class="nounderline abstract_t">Chiang CC, Shahid AH, Harriott AM, et al. Evaluation and treatment of headache associated with moyamoya disease - a narrative review. Cephalalgia 2022; 42:542.</a></li><li><a class="nounderline abstract_t">Li JY, Lai PH, Peng NJ. Moyamoya disease presenting with hemichoreoathetosis and hemidystonia. Mov Disord 2007; 22:1983.</a></li><li><a class="nounderline abstract_t">Kim YO, Kim TS, Woo YJ, et al. Moyamoya disease-induced hemichorea corrected by indirect bypass surgery. Pediatr Int 2006; 48:504.</a></li><li><a class="nounderline abstract_t">Baik JS, Lee MS. Movement disorders associated with moyamoya disease: a report of 4 new cases and a review of literatures. Mov Disord 2010; 25:1482.</a></li><li><a class="nounderline abstract_t">Lin N, Baird L, Koss M, et al. Discovery of asymptomatic moyamoya arteriopathy in pediatric syndromic populations: radiographic and clinical progression. Neurosurg Focus 2011; 31:E6.</a></li><li><a class="nounderline abstract_t">Kuroda S, Hashimoto N, Yoshimoto T, et al. Radiological findings, clinical course, and outcome in asymptomatic moyamoya disease: results of multicenter survey in Japan. Stroke 2007; 38:1430.</a></li><li><a class="nounderline abstract_t">Yamada M, Fujii K, Fukui M. [Clinical features and outcomes in patients with asymptomatic moyamoya disease--from the results of nation-wide questionnaire survey]. No Shinkei Geka 2005; 33:337.</a></li><li><a class="nounderline abstract_t">Rafay MF, Armstrong D, Dirks P, et al. Patterns of cerebral ischemia in children with moyamoya. Pediatr Neurol 2015; 52:65.</a></li><li><a class="nounderline abstract_t">Kim JM, Lee SH, Roh JK. Changing ischaemic lesion patterns in adult moyamoya disease. J Neurol Neurosurg Psychiatry 2009; 80:36.</a></li><li><a class="nounderline abstract_t">Takahashi M, Miyauchi T, Kowada M. Computed tomography of Moyamoya disease: demonstration of occluded arteries and collateral vessels as important diagnostic signs. Radiology 1980; 134:671.</a></li><li><a class="nounderline abstract_t">Handa J, Nakano Y, Okuno T, et al. Computerized tomography in Moyamoya syndrome. Surg Neurol 1977; 7:315.</a></li><li><a class="nounderline abstract_t">Kikuta K, Takagi Y, Nozaki K, et al. Asymptomatic microbleeds in moyamoya disease: T2*-weighted gradient-echo magnetic resonance imaging study. J Neurosurg 2005; 102:470.</a></li><li><a class="nounderline abstract_t">Kikuta K, Takagi Y, Nozaki K, et al. The presence of multiple microbleeds as a predictor of subsequent cerebral hemorrhage in patients with moyamoya disease. Neurosurgery 2008; 62:104.</a></li><li><a class="nounderline abstract_t">Kuroda S, Kashiwazaki D, Ishikawa T, et al. Incidence, locations, and longitudinal course of silent microbleeds in moyamoya disease: a prospective T2*-weighted MRI study. Stroke 2013; 44:516.</a></li><li><a class="nounderline abstract_t">Roach ES, Golomb MR, Adams R, et al. Management of stroke in infants and children: a scientific statement from a Special Writing Group of the American Heart Association Stroke Council and the Council on Cardiovascular Disease in the Young. Stroke 2008; 39:2644.</a></li><li><a class="nounderline abstract_t">Ohta T, Tanaka H, Kuroiwa T. Diffuse leptomeningeal enhancement, "ivy sign," in magnetic resonance images of moyamoya disease in childhood: case report. Neurosurgery 1995; 37:1009.</a></li><li><a class="nounderline abstract_t">Maeda M, Tsuchida C. "Ivy sign" on fluid-attenuated inversion-recovery images in childhood moyamoya disease. AJNR Am J Neuroradiol 1999; 20:1836.</a></li><li><a class="nounderline abstract_t">Chung PW, Park KY. Leptomeningeal enhancement in petients with moyamoya disease: correlation with perfusion imaging. Neurology 2009; 72:1872.</a></li><li><a class="nounderline abstract_t">Mori N, Mugikura S, Higano S, et al. The leptomeningeal "ivy sign" on fluid-attenuated inversion recovery MR imaging in Moyamoya disease: a sign of decreased cerebral vascular reserve? AJNR Am J Neuroradiol 2009; 30:930.</a></li><li><a class="nounderline abstract_t">Azizyan A, Sanossian N, Mogensen MA, Liebeskind DS. Fluid-attenuated inversion recovery vascular hyperintensities: an important imaging marker for cerebrovascular disease. AJNR Am J Neuroradiol 2011; 32:1771.</a></li><li><a class="nounderline abstract_t">Horie N, Morikawa M, Nozaki A, et al. "Brush Sign" on susceptibility-weighted MR imaging indicates the severity of moyamoya disease. AJNR Am J Neuroradiol 2011; 32:1697.</a></li><li><a class="nounderline abstract_t">Yu X, Yuan L, Jackson A, et al. Prominence of Medullary Veins on Susceptibility-Weighted Images Provides Prognostic Information in Patients with Subacute Stroke. AJNR Am J Neuroradiol 2016; 37:423.</a></li><li><a class="nounderline abstract_t">Muraoka S, Araki Y, Taoka T, et al. Prediction of Intracranial Arterial Stenosis Progression in Patients with Moyamoya Vasculopathy: Contrast-Enhanced High-Resolution Magnetic Resonance Vessel Wall Imaging. World Neurosurg 2018; 116:e1114.</a></li><li><a class="nounderline abstract_t">Ryoo S, Cha J, Kim SJ, et al. High-resolution magnetic resonance wall imaging findings of Moyamoya disease. Stroke 2014; 45:2457.</a></li><li><a class="nounderline abstract_t">Kodama N, Aoki Y, Hiraga H, et al. Electroencephalographic findings in children with moyamoya disease. Arch Neurol 1979; 36:16.</a></li><li><a class="nounderline abstract_t">Cho A, Chae JH, Kim HM, et al. Electroencephalography in pediatric moyamoya disease: reappraisal of clinical value. Childs Nerv Syst 2014; 30:449.</a></li><li><a class="nounderline abstract_t">Frechette ES, Bell-Stephens TE, Steinberg GK, Fisher RS. Electroencephalographic features of moyamoya in adults. Clin Neurophysiol 2015; 126:481.</a></li><li><a class="nounderline abstract_t">Smith ER. Moyamoya arteriopathy. Curr Treat Options Neurol 2012; 14:549.</a></li><li><a class="nounderline abstract_t">Kim HY, Chung CS, Lee J, et al. Hyperventilation-induced limb shaking TIA in Moyamoya disease. Neurology 2003; 60:137.</a></li><li><a class="nounderline abstract_t">Spengos K, Tsivgoulis G, Toulas P, et al. Hyperventilation-enhanced chorea as a transient ischaemic phenomenon in a patient with moyamoya disease. Eur Neurol 2004; 51:172.</a></li><li><a class="nounderline abstract_t">Bakdash T, Cohen AR, Hempel JM, et al. Moyamoya, dystonia during hyperventilation, and antiphospholipid antibodies. Pediatr Neurol 2002; 26:157.</a></li><li><a class="nounderline abstract_t">Tsuchiya K, Makita K, Furui S. Moyamoya disease: diagnosis with three-dimensional CT angiography. Neuroradiology 1994; 36:432.</a></li><li><a class="nounderline abstract_t">Hasuo K, Mihara F, Matsushima T. MRI and MR angiography in moyamoya disease. J Magn Reson Imaging 1998; 8:762.</a></li><li><a class="nounderline abstract_t">Yamada I, Nakagawa T, Matsushima Y, Shibuya H. High-resolution turbo magnetic resonance angiography for diagnosis of Moyamoya disease. Stroke 2001; 32:1825.</a></li><li><a class="nounderline abstract_t">Suzuki J, Kodama N. Moyamoya disease--a review. Stroke 1983; 14:104.</a></li><li><a class="nounderline abstract_t">Suzuki J, Takaku A. Cerebrovascular "moyamoya" disease. Disease showing abnormal net-like vessels in base of brain. Arch Neurol 1969; 20:288.</a></li></ol></div><div id="topicVersionRevision">Topic 1131 Version 42.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22462697" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Spontaneous occlusion of the circle of Willis in children: pediatric moyamoya summary with proposed evidence-based practice guidelines. A review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9409446" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Guidelines for the diagnosis and treatment of spontaneous occlusion of the circle of Willis ('moyamoya' disease). Research Committee on Spontaneous Occlusion of the Circle of Willis (Moyamoya Disease) of the Ministry of Health and Welfare, Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24402480" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Advances and surgical considerations in the treatment of moyamoya disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22870528" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Guidelines for diagnosis and treatment of moyamoya disease (spontaneous occlusion of the circle of Willis).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22870528" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Guidelines for diagnosis and treatment of moyamoya disease (spontaneous occlusion of the circle of Willis).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21048783" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : A genome-wide association study identifies RNF213 as the first Moyamoya disease gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21799892" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Identification of RNF213 as a susceptibility gene for moyamoya disease and its possible role in vascular development.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22377813" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Homozygous c.14576G&gt;A variant of RNF213 predicts early-onset and severe form of moyamoya disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10754001" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Linkage of familial moyamoya disease (spontaneous occlusion of the circle of Willis) to chromosome 17q25.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18463369" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Autosomal dominant moyamoya disease maps to chromosome 17q25.3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23010677" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Identification of a genetic variant common to moyamoya disease and intracranial major artery stenosis/occlusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23110205" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Molecular analysis of RNF213 gene for moyamoya disease in the Chinese Han population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26125557" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Adult Moyamoya Disease: A Burden of Intracranial Stenosis in East Asians?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31949090" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Predictive role of heterozygous p.R4810K of RNF213 in the phenotype of Chinese moyamoya disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9973290" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Mapping of a familial moyamoya disease gene to chromosome 3p24.2-p26.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10757474" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Linkage analysis of moyamoya disease on chromosome 6.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15362573" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : A novel susceptibility locus for moyamoya disease on chromosome 8q23.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16788009" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Inheritance pattern of familial moyamoya disease: autosomal dominant mode and genomic imprinting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29273593" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Novel Susceptibility Loci for Moyamoya Disease Revealed by a Genome-Wide Association Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17721051" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Stenosis of the proximal external carotid artery in an adult with moyamoya disease: moyamoya or atherosclerotic change?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17372129" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Moyamoya following cranial irradiation for primary brain tumors in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/121867" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : "Moya-moya' disease caused by cranial trauma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10855525" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Moyamoya disease associated with a brain stem glioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1280777" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Moyamoya disease associated with pituitary adenoma--report of two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6719333" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Moyamoya disease associated with craniopharyngioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15654044" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Postinfectious vasculopathy with evolution to moyamoya syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9409442" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The relationship between moyamoya disease and bacterial infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18035245" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Case of moyamoya disease in a patient with advanced acquired immunodeficiency syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26961262" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Moyamoya Syndrome in South African Children With HIV-1 Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14580655" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Sickle cell anemia with moyamoya disease: outcomes after EDAS procedure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11964276" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Moyamoya syndrome in childhood sickle cell disease: a predictive factor for recurrent cerebrovascular events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15279758" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Stroke in Children with Sickle Cell Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18206795" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Moyamoya disease associated with hemoglobin Fairfax and beta-thalassemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7746424" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Fanconi anemia and moyamoya: evidence for an association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11483402" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Moyamoya syndrome with spherocytosis: effect of splenectomy on strokes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17385096" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Atherosclerotic adult Moya-Moya disease in a patient with hyperhomocysteinaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/655914" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Moyamoya and Hageman factor (Factor XII) deficiency in a black adult.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16020757" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Moyamoya syndrome in an adolescent with essential thrombocythemia: successful intracranial carotid stent placement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16302575" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Moyamoya syndrome with inherited proteins C and S deficiency: report of one case.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9367301" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Moyamoya disease and protein S deficiency: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25207193" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Protein S Deficiency and an Adult Case with Moyamoya Syndrome that Presented with Primary Intraventricular Haemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17621533" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Moya moya syndrome in a child with pyruvate kinase deficiency and combined prothrombotic factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23574743" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Systemic lupus erythematosus associated with Moyamoya syndrome: a case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6150852" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Cerebral angiography in vasculitis affecting the nervous system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16755098" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Co-morbidity of moyamoya disease with Graves' disease. report of three cases and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16028759" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Moyamoya disease associated with Graves disease: special considerations regarding clinical significance and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2070296" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Graves' thyrotoxicosis and Moyamoya disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23652271" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Moyamoya disease in a primarily white, midwestern US population: increased prevalence of autoimmune disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17895140" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Moyamoya syndrome associated with Sneddon's syndrome and antiphospholipid-protein antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11486106" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Prothrombotic disorders in children with moyamoya syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1859480" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Cerebral vasculopathy associated with collateralization resembling moya moya phenomenon and with anti-Ro/SS-A and anti-La/SS-B antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16645269" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Moyamoya-like vascular abnormality in pulmonary sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9805902" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Moyamoya disease associated with pulmonary sarcoidosis--case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14993126" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Vascular anomalies in Alagille syndrome: a significant cause of morbidity and mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22759690" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Moyamoya vascular pattern in Alagille syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16263984" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Moyamoya syndrome associated with Down syndrome: outcome after surgical revascularization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12161901" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Moyamoya disease and Down syndrome: case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16417866" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Hypomelanosis of Ito and Moyamoya disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10929734" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Marfan syndrome associated with moyamoya phenomenon and aortic dissection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27611897" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Surgical outcomes of Majewski osteodysplastic primordial dwarfism Type II with intracranial vascular anomalies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20644152" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : A hereditary moyamoya syndrome with multisystemic manifestations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21596366" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Loss of BRCC3 deubiquitinating enzyme leads to abnormal angiogenesis and is associated with syndromic moyamoya.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17101839" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Intraventricular hemorrhage disclosing neurofibromatosis 1 and moyamoya phenomena.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9075025" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Case of von Recklinghausen disease associated with cerebral infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15699396" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Cerebrovascular abnormalities in a population of children with neurofibromatosis type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35849956" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Characteristics of Moyamoya Syndrome in Pediatric Patients With Neurofibromatosis Type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26778511" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Management of moyamoya syndrome in patients with Noonan syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21763956" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Moyamoya syndrome in a child with Noonan syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9165521" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Noonan syndrome and moyamoya.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10027997" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Phakomatosis pigmentovascularis type IIIb associated with moyamoya disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8937199" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : [A case of Prader-Willi syndrome with bilateral middle cerebral artery occlusion and moyamoya phenomenon].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16086762" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Elastosis perforans serpiginosa-like pseudoxanthoma elasticum in a child with severe Moya Moya disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7307643" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Recurrent thrombotic deterioration in the Sturge-Weber syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/713951" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Tuberous sclerosis with moyamoya disease. Case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16987153" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Moyamoya syndrome in a Caucasian woman with Turner's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8460548" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : An autopsied case of Williams syndrome complicated by moyamoya disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15480611" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Morning glory disc anomaly, midline cranial defects and abnormal carotid circulation: an association worth looking for.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11070437" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Basal meningoencephalocele, anomaly of optic disc and panhypopituitarism in association with moyamoya disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10779846" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Morning glory disk anomaly, choroidal coloboma, and congenital constrictive malformations of the internal carotid arteries (moyamoya disease).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10774998" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Moyamoya disease (moyamoya syndrome) and coarctation of the aorta.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9417151" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Moyamoya syndrome associated with congenital heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14681758" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Moyamoya and extracranial vascular involvement: fibromuscular dysplasia? A report of two children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10700512" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Renal artery lesions in patients with moyamoya disease: angiographic findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6938175" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Moyamoya disease in a patient with type I glycogenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9208417" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Moyamoya disease in a child with glycogen storage disease type Ia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10453193" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Moya Moya syndrome in a child with hyperphosphatasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9645982" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Thrombo-embolic stroke, moya-moya phenomenon and primary oxalosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2756542" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Moyamoya disease associated with polycystic kidney disease and eosinophilic granuloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23419477" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Caucasian familial moyamoya syndrome with rare multisystemic malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9409404" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Risk factors of moyamoya disease in Canada and the USA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6504578" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Pathology of so-called "spontaneous occlusion of the circle of Willis".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6524230" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : [A case of fibromuscular dysplasia in an unusual location].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7269227" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Cerebral haemorrhage in Moyamoya disease at autopsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4736492" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Progressive alternating hemiplegia in early childhood and basal arterial stenosis and telangiectasia (moyamoya syndrome).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7422063" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : [Transdural anastomosis in moyamoya disease--vault moyamoy (author's transl)].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/632880" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Moyamoya disease associated with aneurysm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/442141" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Intracranial saccular aneurysm and moyamoya disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7229709" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Multiple intracranial aneurysms associated with moyamoya disease. Case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6867923" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Moyamoya disease associated with intracranial aneurysms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3990927" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Aneurysms associated with moyamoya disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Intracranial aneurysm in moyamoya disease: report of ten cases and review of the literature</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1750042" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Systemic vascular changes in spontaneous occlusion of the circle of Willis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2988231" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Wilms' tumor associated with Moyamoya disease: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35605621" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Moyamoya disease: diagnosis and interventions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19095988" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Increased levels of circulating endothelial progenitor cells in patients with Moyamoya disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29219755" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Mitochondrial abnormalities related to the dysfunction of circulating endothelial colony-forming cells in moyamoya disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19965844" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Plasma matrix metalloproteinases, cytokines and angiogenic factors in moyamoya disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7936147" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Immunohistochemical reactions for fibroblast growth factor receptor in arteries of patients with moyamoya disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9577971" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Elevation of cerebrospinal fluid levels of basic fibroblast growth factor in moyamoya and central nervous system disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9303017" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Increase in elastin gene expression and protein synthesis in arterial smooth muscle cells derived from patients with Moyamoya disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9761057" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Role of transforming growth factor-beta1 in the pathogenesis of moyamoya disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15528455" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Increased expression of hepatocyte growth factor in cerebrospinal fluid and intracranial artery in moyamoya disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1987677" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Recurrent transient ischemic attacks and stroke in association with an internal carotid artery web.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25733922" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Moyamoya disease and syndromes: from genetics to clinical management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18275294" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Progression of disease in unilateral moyamoya syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32710766" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Clinical Course of Unilateral Moyamoya Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6823686" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Histopathology of the brain vascular network in moyamoya disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9409438" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Histopathological studies on spontaneous occlusion of the circle of Willis (cerebrovascular moyamoya disease).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17245006" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Histological features of middle cerebral arteries from patients treated for Moyamoya disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8980731" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Characteristics of intracranial aneurysms associated with moyamoya disease. A review of 111 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15208124" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Prevalence of stenoocclusive lesions in the renal and abdominal arteries in moyamoya disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1282678" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Worldwide distribution of moyamoya disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16186547" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Moyamoya disease in Washington State and California.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9409395" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Epidemiological features of moyamoya disease in Japan: findings from a nationwide survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18048855" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Prevalence and clinicoepidemiological features of moyamoya disease in Japan: findings from a nationwide epidemiological survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18077479" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Novel epidemiological features of moyamoya disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31234758" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Characteristics of Moyamoya Disease Based on National Registry Data in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22418580" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Moyamoya disorder in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24499994" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Nationwide survey on quasi-moyamoya disease in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28109734" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Clinical Characteristics and Natural History of Quasi-Moyamoya Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21397174" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Moyamoya disease in early infancy: case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26320201" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Early-onset bilateral cerebral arteriopathies: Cohort study of phenotype and disease course.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22020027" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Moyamoya disease in China: its clinical features and outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28715924" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Moyamoya Disease in Children: Results From the International Pediatric Stroke Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22378916" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Regional differences in incidence and patient characteristics of moyamoya disease: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18787200" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Moyamoya disease in Europeans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25037198" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Adult moyamoya disease in an urban center in the United States is associated with a high burden of watershed ischemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19297575" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Moyamoya disease and moyamoya syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9409399" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Epidemiological study of moyamoya disease in Taiwan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9409406" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Clinical and neuroradiological findings of moyamoya disease in Italy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9409397" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Natural history of moyamoya disease: comparison of activity of daily living in surgery and non surgery groups.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9409397" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Natural history of moyamoya disease: comparison of activity of daily living in surgery and non surgery groups.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22693130" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Moyamoya disease-related versus primary intracerebral hemorrhage: [corrected] location and outcomes are different.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26313681" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Moyamoya disease presenting with subarachnoid hemorrhage: Clinical features and neuroimaging of a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26846755" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Moyamoya Disease: Epidemiology, Clinical Features, and Diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37271055" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Seizures in Pediatric Moyamoya: Risk Factors and Functional Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16302616" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Headache in pediatric moyamoya disease: review of 204 consecutive cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27112705" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Headache in Caucasian patients with Moyamoya angiopathy - a systematic cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34786968" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Evaluation and treatment of headache associated with moyamoya disease - a narrative review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17657809" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Moyamoya disease presenting with hemichoreoathetosis and hemidystonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16970793" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Moyamoya disease-induced hemichorea corrected by indirect bypass surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20629162" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Movement disorders associated with moyamoya disease: a report of 4 new cases and a review of literatures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22133171" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Discovery of asymptomatic moyamoya arteriopathy in pediatric syndromic populations: radiographic and clinical progression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17395863" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Radiological findings, clinical course, and outcome in asymptomatic moyamoya disease: results of multicenter survey in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15830539" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : [Clinical features and outcomes in patients with asymptomatic moyamoya disease--from the results of nation-wide questionnaire survey].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25459363" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Patterns of cerebral ischemia in children with moyamoya.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18450791" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Changing ischaemic lesion patterns in adult moyamoya disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7355216" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : Computed tomography of Moyamoya disease: demonstration of occluded arteries and collateral vessels as important diagnostic signs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/871006" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : Computerized tomography in Moyamoya syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15796381" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : Asymptomatic microbleeds in moyamoya disease: T2*-weighted gradient-echo magnetic resonance imaging study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18300897" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : The presence of multiple microbleeds as a predictor of subsequent cerebral hemorrhage in patients with moyamoya disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23223508" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : Incidence, locations, and longitudinal course of silent microbleeds in moyamoya disease: a prospective T2*-weighted MRI study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18635845" id="rid162" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>163 : Management of stroke in infants and children: a scientific statement from a Special Writing Group of the American Heart Association Stroke Council and the Council on Cardiovascular Disease in the Young.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8559324" id="rid163" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>164 : Diffuse leptomeningeal enhancement, "ivy sign," in magnetic resonance images of moyamoya disease in childhood: case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10588105" id="rid164" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>165 : "Ivy sign" on fluid-attenuated inversion-recovery images in childhood moyamoya disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19470971" id="rid165" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>166 : Leptomeningeal enhancement in petients with moyamoya disease: correlation with perfusion imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19246527" id="rid166" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>167 : The leptomeningeal "ivy sign" on fluid-attenuated inversion recovery MR imaging in Moyamoya disease: a sign of decreased cerebral vascular reserve?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21051516" id="rid167" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>168 : Fluid-attenuated inversion recovery vascular hyperintensities: an important imaging marker for cerebrovascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21799039" id="rid168" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>169 : "Brush Sign" on susceptibility-weighted MR imaging indicates the severity of moyamoya disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26514606" id="rid169" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>170 : Prominence of Medullary Veins on Susceptibility-Weighted Images Provides Prognostic Information in Patients with Subacute Stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29864569" id="rid170" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>171 : Prediction of Intracranial Arterial Stenosis Progression in Patients with Moyamoya Vasculopathy: Contrast-Enhanced High-Resolution Magnetic Resonance Vessel Wall Imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24947295" id="rid171" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>172 : High-resolution magnetic resonance wall imaging findings of Moyamoya disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/420596" id="rid172" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>173 : Electroencephalographic findings in children with moyamoya disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23943190" id="rid173" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>174 : Electroencephalography in pediatric moyamoya disease: reappraisal of clinical value.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25065300" id="rid174" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>175 : Electroencephalographic features of moyamoya in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22865293" id="rid175" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>176 : Moyamoya arteriopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12525739" id="rid176" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>177 : Hyperventilation-induced limb shaking TIA in Moyamoya disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15079090" id="rid177" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>178 : Hyperventilation-enhanced chorea as a transient ischaemic phenomenon in a patient with moyamoya disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11897484" id="rid178" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>179 : Moyamoya, dystonia during hyperventilation, and antiphospholipid antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7991085" id="rid179" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>180 : Moyamoya disease: diagnosis with three-dimensional CT angiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9702875" id="rid180" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>181 : MRI and MR angiography in moyamoya disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11486112" id="rid181" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>182 : High-resolution turbo magnetic resonance angiography for diagnosis of Moyamoya disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6823678" id="rid182" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>183 : Moyamoya disease--a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5775283" id="rid183" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>184 : Cerebrovascular "moyamoya" disease. Disease showing abnormal net-like vessels in base of brain.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
